Drug Profile
Research programme: Parkinson's disease therapy - AbbVie
Alternative Names: Supplemental D2/D3 agonist for Parkinson's diseaseLatest Information Update: 18 May 2020
Price :
$50
*
At a glance
- Originator MAP Pharmaceuticals
- Developer AbbVie
- Class
- Mechanism of Action Dopamine D2 receptor agonists; Dopamine D3 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 16 Jul 2016 No recent reports of development identified for preclinical development in Parkinson's-disease in USA (Inhalation, Inhalant)
- 01 Mar 2013 MAP Pharmaceuticals has been acquired by Allergan